No Data
No Data
No Data
No Data
No Data
Asia Pacific's largest biotech CRO Novell Health passed the Hong Kong Stock Exchange hearing. TPG and Sequoia are shareholders, and the target valuation may exceed 4 billion US dollars
According to previous reports, Novi Health will conduct a pre-roadshow this week. The company's target valuation exceeds 4 billion US dollars and is expected to raise 1.5 billion US dollars (about 11.65 billion Hong Kong dollars).
獨角獸早知道Sep 7, 2021 08:52 · IPO
New share news | Novak Health is heard by the Hong Kong Stock Exchange, Q1 has a net loss of US $14.558 million in 2021
Novi Health Technology Holdings Co., Ltd. is a contract research organization specializing in serving biotechnology companies in the Asia-Pacific region.
智通財經Sep 6, 2021 07:49
No Data
No Data